- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00898521
Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns
Feasibility Study: Enzymatic Debridement in Patients With Partial Thickness Burns (Children & Adults)- Protocol MW2008-09-03
Burns represent one of the most severe and dreaded traumas. Burned and traumatized tissue is known as eschar. The dead eschar, if not removed, often becomes heavily contaminated and is the source of local and/or systemic infection or sepsis. The local inflammation and infection destroy healthy surrounding tissues and extends the original damage. In order to prevent these complications, and in order to minimize the risk of infection, it is imperative to evaluate the burn and remove all of the offending eschar at the earliest possible opportunity. This removal of dead tissue is termed "debridement".
The most direct debridement method for eschar removal is surgery. Traditional, conservative non-surgical debridement is a lengthy process which often involves many complications.
The objectives of this study are as follows:
- To evaluate the safety and efficacy (exploratory) of DGD in hospitalized patients with Partial Thickness (mid and deep dermal) thermal burns of 4-30% total body surface area (TBSA), but with total burn wounds of no more than 30% TBSA. Measures have already been taken in previous studies involving deeper wounds to control safety parameters (such as pain, fever and infection). Nevertheless, as part of the effort to expand the burn population in the future phase 3 study to the more superficial wound group, it is important to first explore these parameters in a small group involving this burn population.
- To explore DGD absorption as measured by Pharmacokinetic testing.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females between 2 years and 55 years of age,
- Thermal burns caused by fire/flame, scalds or contact,
Burn composition must be as follows:
- Partial Thickness (mid & deep dermal) burn wounds ≥ 4% and ≤ 30% Total Body Surface Area (TBSA),
- Full thickness burns ≤ 5%,
- All the partial and full thickness burn wounds must receive study treatment except facial, genital or perineal burns (Exclusion Criteria #5 and #6 below),
- Total burn wounds ≤ 30% TBSA,
- Hospital admission within 24 hours of the burn injury. Patients transferred from another hospital/clinic may be enrolled if the primary admission was within 24 hours of the burn injury and admission to the burn unit participating in the study was within 48 hours of the burn injury,
- Signed written informed consent.
Exclusion Criteria:
- More than 5% TBSA full thickness burns,
- Patient having only full thickness burns,
- Other severe cutaneous trauma at the same sites as the burns (i.e. considerable blunt, avulsion or deep abrasion), or previous burn(s) at the same treatment site(s),
- One or more burn wounds that do not meet study criteria,
- Deep partial thickness and/or full thickness facial burn wounds >0.5% TBSA; study treatment of facial burns is not allowed,
- Study treatment of perineal and/or genital burns is not allowed; A patient with these wounds may be enrolled but the wounds may not be designated as target wounds,
- Patient with circumferential anterior/posterior trunk fire/flame burns, >15% TBSA Circumferential is defined as encircling ≥ 80% of the trunk circumference),
- A. The following pre enrolment dressings: a. Flammacerium, b. Silver Nitrate AgNO3), B. Pre-enrolment wounds which are covered by eschar heavily saturated with iodine or by pseudoeschar (e.g. pseudoeschar as a result of SSD treatment);
- Pre-enrolment escharotomy,
- Heavily contaminated burns or pre-existing infections (Adults: WBC ≥ 20.0 X 103 cells/µL; Children aged 4-18: WBC ≥ 25.0 X 103 cells/µL)),11.Signs that may indicate smoke inhalation (e.g. clinical signs, etiology of injury, venue of injury, etc.),
- Children with Hb < 10 gm/dl at Screening/Pre treatment
- Prisoners,
- Pregnant women (positive pregnancy test) or nursing mothers,
- Poorly controlled diabetes mellitus (HbA1c>9%),
- Cardio-pulmonary disease (MI within 4 weeks prior to injury, pulmonary hypertension, COPD or pre-existing oxygen-dependent pulmonary diseases),
- Pre-existing diseases which interfere with circulation (PVD, edema, lymphedema, surgery to the regional lymph nodes, obesity, varicose veins),
- Immediate life threatening conditions (such as immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, cardiovascular, liver or neoplastic disease),
- Chronic systemic steroid intake,
- History of allergy and/or known sensitivity to pineapples or papain,
- Current suicide attempt,
- Participation in another investigational drug trial,
- Current alcohol or drug abuse,
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DGD
|
DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem. Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA). Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement. The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use. DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions. DGD should not be applied more than twice to the same burn wound area. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint is safety as measured by: 1. Systemic an local adverse events, 2. Changes in vital signs and laboratory tests, 3. Time to wound closure.
Time Frame: Throughout the study
|
Throughout the study
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MW2008-09-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burn
-
Xequel Bio, Inc.United States Department of DefenseWithdrawnThermal Burn | Second Degree Burn
-
Indonesia UniversityRecruitingBurn Degree Second | Burn Degree ThirdIndonesia
-
XenoTherapeutics, Inc.Joseph M. Still Research Foundation, Inc.Active, not recruitingWound Heal | Thermal Burn | Burn Degree Second | Burns Degree Third | Burn (Disorder)United States
-
University Hospital Schleswig-HolsteinUniversity of LuebeckRecruitingSecond-degree Burn | Third-Degree BurnGermany
-
General Electric ResearchRecruitingBurn Wound | 2nd Degree Burn of the SkinUnited States
-
University Hospital, LinkoepingCompletedBurn Scar | Burns | Burn Second DegreeSweden
-
University of AlbertaRecruitingBurn Degree Second | Burn; Multiple Body Regions, Max. Second Degree | Third-Degree BurnCanada
-
S.K. Lerik General HospitalCompletedBurn Scar | Burns | Burn Degree Second | Electrical BurnIndonesia
-
Regenera Pharma LtdWithdrawnPartial Thickness Burn | Second Degree Burn Less Than 5%TBSAIsrael
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
Clinical Trials on DGD
-
MediWound LtdCompletedBurnPoland, Australia, Brazil, France, Germany, Israel, Italy, Romania, Slovakia, United Kingdom